Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bintrafusp alfa in advanced unresectable cervical cancer
CTR20201516Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- Aug 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of bintrafusp alfa in Cervical Cancer (CC), sponsored by Merck KGaA. Started Aug 2020; status: completed.
02
Drugs
bintrafusp alfa
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on CTR20201516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201516.